Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease

Abstract

Rapid infusion of infliximab is safe and well tolerated, with no increase in infusion-related reactions. Where reactions do occur, they are usually mild, allowing completion of therapy.

A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study

“…The observation that in infliximab, naïve patients and after six 2‐h infusions switch to a 1‐h infliximab maintenance infusion had a similar infusion reaction rate as a 2‐h infliximab maintenance infusion is consistent with the current literatures 18, 19 . One limitation with our study is the risk of selection bias, because not all eligible patients entered the 1‐h infusion protocol.…”

“…These results demonstrate that a 1‐h infliximab infusion protocol during maintenance therapy is safe and well tolerated. Previous studies have included much smaller numbers of patients and fewer numbers of infusions 16–22 . Indeed the current study has over double the number of total infusions relative to the next largest study.…”

“…Multiple studies examined a shortened infliximab infusion protocol in adult IBD patients 16–20 . In these studies, patients received 0.5–1.5‐h infusion with no apparent increase in infusion reactions relative to a 2‐h infusion.…”

A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease

“…A recent metaanalysis found the presence of these antibodies associated with a higher risk of acute, but not delayed infusion reactions [18]. The concomitant use of immunomodulators has consequently been recommended to contain the rate of these reactions [19,20], but current data on their efficacy are conflicting [10,13,16,21]. Our multivariate analysis indicated that the concomitant use of immunomodulators is not a protective factor, though only a small proportion of the patients in our sample were taking these drugs.…”

Letter: the feasibility and safety of accelerated infliximab infusions in patients with inflammatory bowel disease

“…incomplete data and different definitions for infusions reactions), it confirms that rapid IFX infusions in selected patients are not associated with an increased risk of adverse events. [2][3][4][5][6] This strategy could save costs and have a substantial impact on healthcare resources and absenteeism from work or school. sions (Phase-M) proceeded to phases 2 and 3.…”